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CD4+CD25+Foxp3+ regulatory T cells (Tregs) are functionally distinct subsets of mature T
cells with broad suppressive activity and have been shown to play an important role in the
establishment of immune tolerance after allogeneic hematopoietic stem cell
transplantation (HSCT). Tregs exhibit an activated phenotype from the stage of
emigration from the thymus and maintain continuous proliferation in the periphery. The
distinctive feature in homeostasis enables Tregs to respond sensitively to small
environmental changes and exert necessary and sufficient immune suppression;
however, on the other hand, it also predisposes Tregs to be susceptible to apoptosis in
the inflammatory condition post-transplant. Our studies have attempted to define the
intrinsic and extrinsic factors affecting Treg homeostasis from the acute to chronic phases
after allogeneic HSCT. We have found that altered cytokine environment in the prolonged
post-HSCT lymphopenia or peri-transplant use of immune checkpoint inhibitors could
hamper Treg reconstitution, leading to refractory graft-versus-host disease. Using murine
models and clinical trials, we have also demonstrated that proper intervention with low-
dose interleukin-2 or post-transplant cyclophosphamide could restore Treg homeostasis
and further amplify the suppressive function after HSCT. The purpose of this review is to
reconsider the distinctive characteristics of post-transplant Treg homeostasis and discuss
how to harness Treg homeostasis to optimize posttransplant immunity for developing a
safe and efficient therapeutic strategy.
Keywords: regulatory T cell, graft-versus-host disease, interleukin 2, immune checkpoint inhibitor, post-
transplant cyclophosphamideINTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment strategy for
patients with various hematological disorders (1). However, graft-versus-host disease (GVHD)
remains a cause of significant morbidity and mortality following HSCT (2, 3). The pathophysiology
of acute GVHD is the response of donor-derived effector T cells to recipient tissues, including the
skin, gut, and liver. During the early phase after HSCT, these immune reactions also evoke
dysregulated reconstitution of T and B cell subsets, leading to the basic pathogenesis of theorg August 2021 | Volume 12 | Article 7133581
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has been increasing evidence showing that regulatory T cells
(Tregs) play a critical role in the regulation of acute and chronic
GVHD, and the robust reconstitution of Tregs is needed to
reestablish a well-balanced immune system that can maintain
appropriate levels of peripheral tolerance.
Tregs are a subpopulation of CD4+ T cells that specifically
retain their immunosuppressive functions. Tregs were initially
identified as CD4+CD25+ T cells (5), and subsequent studies have
shown that Forkhead box P3 (Foxp3) is a master transcription
factor for this subset (6). Mice lacking Foxp3 expression were seen
to develop lethal autoimmune diseases (7), and humans with a
mutation in the Foxp3 gene are known to develop immune
dysregulation, polyendocrinopathy, enteropathy, and X-linked
syndrome, which is a severe multiorgan autoimmune disease
(8). Tregs comprise 5–10% of peripheral blood CD4+ T cells in
healthy individuals and play an essential role in maintaining
peripheral self-tolerance and preventing autoimmune diseases (9,
10). In the context of allogeneic HSCT, CD4+CD25+ cells were
initially found to be indispensable for immune tolerance against
alloantigens using an in vitro mixed lymphocyte reaction assay
(11). Later, using murine GVHD models, depletion of CD25+
cells from the donor inoculum exacerbated the severity of GVHD,
and co-infusion of ex vivo cultured CD4+CD25+ cells resulted in
significant inhibition of rapidly lethal GVHD in vivo (12). In
addition to murine studies, the analyses of clinical samples from
patients after HSCT demonstrated that the expression of theFrontiers in Immunology | www.frontiersin.org 2Foxp3 gene in peripheral blood mononuclear cells was negatively
correlated with the incidence and severity of clinical acute and
chronic GVHD (13, 14). High Treg contents in the donor graft
were associated with the low incidence of acute GVHD (15).
Further, prospective monitoring of T cell reconstitution
demonstrated that the unbalanced recovery of Tregs and
effector T cells contributed to the development of chronic
GVHD (16, 17). Notably, studies have shown that Tregs do not
abrogate the cytotoxic activity of effector T cells against leukemia
cells, both in vitro and in vivo, suggesting that Tregs could
separate GVHD from graft-versus-tumor (GVT) activity
mediated by donor-derived effector T cells (18). However, in a
human clinical setting, CD25+ T cell-depleted donor lymphocyte
infusion (DLI) showed a better disease control without increasing
the incidence of acute GVHD than unmodified DLI in
contemporaneous patients, indicating the possibility of Treg
suppressive function against the GVT effect (19).
In general, human T cells express CD25 and Foxp3 after
antigen presentation and undergo cell activation. In contrast,
Tregs highly express such activated markers during migration
from the thymus and maintain continuous proliferation in the
periphery (Figure 1). The distinctive feature in homeostasis
enables Tregs to respond sensitively to small environmental
changes and exert necessary and sufficient immune
suppression. However, on the other hand, it also predisposes
Tregs to be susceptible to apoptosis. In patients after allogeneic
HSCT, Tregs are exposed to a profound inflammatoryFIGURE 1 | Development and maintenance of regulatory T cells. Tregs are positively selected from a population with a higher avidity of TCR/MHC-peptide in the
thymus and emigrate to the periphery. Tregs already exhibit an activated phenotype at emigration to the periphery and undergo rapid homeostatic proliferation.
Constitutive proliferation predisposes Tregs to apoptosis. In contrast, Tcons generally undergo slower proliferation and, thus, stable homeostasis with lower
apoptosis. Tcon, conventional T cell; Treg, regulatory T cell; RTE, recent thymic emigrant; TCR, T-cell receptor; MHC, major histocompatibility complex.August 2021 | Volume 12 | Article 713358
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severe lymphopenia, allogeneic antigen stimulation, and altered
cytokine milieu. In addition to such endogenous factors after
HSCT, various therapeutic immune modulators have been
increasingly used in the peri-transplant period in recent years
(Figure 2). Our studies have elucidated that both endogenous
and exogenous factors have major impacts, particularly on Treg
homeostasis and clinical outcomes after allogeneic HSCT.
In this review, we outline the characteristics of posttransplant
Treg homeostasis and discuss how to harness Treg homeostasis
to optimize posttransplant immunity. In particular, we would
attempt to define the intrinsic and extrinsic factors that affect
Treg homeostasis from the acute to chronic phases after
allogeneic HSCT.CHARACTERISTICS OF TREG
HOMEOSTASIS AFTER HSCT
The Generation and Maintenance of Tregs
Tregs are positively selected from populations with a higher
avidity of T cell receptor (TCR)/major histocompatibility
complex-peptide in the thymus and emigrate to the periphery
(Figure 1). Therefore, Tregs can be considered as a
physiologically preactivated population and show distinctive
homeostasis in the periphery (Figure 1). Tregs have a high
turnover and fine sensitivity to a variety of signals from the
environment to regulate the cell number, localization, andFrontiers in Immunology | www.frontiersin.org 3function required to efficiently react to delicate changes in the
immune system (20). Peripheral Tregs exhibit a high basal
proliferation rate compared with conventional T cells (Tcons)
in both mice (21) and humans (22); however, the high
proliferation rate of Tregs is counterbalanced by a high rate of
apoptosis (16). Interleukin-2 (IL-2), which is mainly produced by
effector T cells, plays a pivotal role in Treg homeostasis (20).
Importantly, Tregs cannot produce IL-2 independently;
therefore, homeostasis critically depends on the extrinsic
cytokine environment of the cell.
The Reconstitution of T Cell Subsets and
Immune Tolerance
The reconstitution of T cell subsets after HSCT is a polymorphic
and long-term process. In general, the initial phase of T cell
reconstitution is primarily dependent on the peripheral
expansion of mature T cells that are contained in the stem cell
graft (23). This process is promoted by lymphopenia-induced
signals and the stimulation of donor T cells by alloantigens (16).
Hematopoietic stem cells (HSC) also differentiate through the
thymus, and thymus-derived T cells are then exported to the
periphery. However, thymus-dependent generation of donor T
cells is generally delayed and incomplete in adult patients
because of natural thymic involution and damage, especially in
thymic epithelial cells, resulting from high-dose chemotherapy
and irradiation administered as part of the conditioning regimen
(24–28). Once naïve T cells are exported into the periphery from
the thymus, they are subject to homeostatic signals that regulateFIGURE 2 | The balance between effector T cells and Tregs in the distinct post-HSCT environment. After HSCT, donor-derived T cells are exposed to a variety of
endogenous factors, including lymphopenia, alloantigens, danger signals, and cytokine storm, which affect the reconstitution of donor-derived immune cells. In
addition, therapeutic interventions that have immunomodulating effects during the peri-transplant period also affect donor-derived T cell homeostasis. Unbalanced
immune reconstitution may provide a basis for the pathogenesis of GVHD. In contrast, favorable Treg recovery in the post-transplant environment results in the
induction of immune tolerance. GVHD, graft-versus-host disease; Treg, regulatory T cell; HSCT, hematopoietic stem cell transplantation; IL-2: interleukin 2, ICI,
immune checkpoint inhibitor; PTCy, post-transplant cyclophosphamide.August 2021 | Volume 12 | Article 713358
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maintain the total number of T cell subsets at an appropriate
level. Although the transition of peripheral T cells frommature T
cells in the stem cell graft into thymic-generated naïve T cells is
commonly observed in each T cell lineage after HSCT; each T cell
subset is subject to distinct homeostatic controls in the periphery
(29). Particularly, Treg homeostasis appears to be distinct from
Tcon, and this may contribute to an imbalance between Treg and
Tcon (Figure 2) (10, 22). We previously studied long-term Treg
reconstitution after clinical HSCT and the impacts on the
development of chronic GVHD (16). Our data indicated that
thymic generation of Tregs was markedly impaired, while this
subset maintained a significantly higher level of proliferation as
compared to Tcons. Treg proliferation in vivo appears to be
driven primarily by CD4 lymphopenia. Importantly, high levels
of Treg proliferation are counterbalanced by its increased
susceptibility to apoptosis. Altered Treg homeostasis in
response to the homeostatic pressure under prolonged CD4
lymphopenia resulted in the selective peripheral depletion of
Tregs and the subsequent development of chronic GVHD.
A recent study that analyzed CD4+Treg heterogeneity with a
large panel of functional markers using mass cytometry by time
of flight revealed that in addition to the numerical deficiency,
reduced heterogeneity of CD4+Tregs was associated with the
development of chronic GVHD (30). Thus, the thymic
generation of de novo Tregs from donor HSC plays an
essential role in long-term immune reconstitution. In addition
to Treg heterogeneity, foxp3 stability (31) is also important for
Treg survival and GVHD suppression (32–34). The post-
transplant inflammatory environment may affect the genetic
stability of Tregs and should be taken into consideration for
the understandings of Treg homeostasis after HSCT.
In addition to donor-derived Tregs, host-derived Tregs
appear to play a crucial role in immune tolerance, especially
during the very early phase after HSCT. Since Tregs are relatively
radioresistant (35), murine studies showed that host Tregs could
survive for several weeks after HSCT and contribute to
suppressing the alloimmune response in the experimental mice
model in the low level of irradiation before HSCT (36).
The Basic Framework of Treg
Reconstitution After Clinical HSCT
Based on the above findings, we proposed a basic framework of
Treg reconstitution after clinical HSCT (Figure 3) (37). It comprises
four phases: Treg expansion, transition, repopulation, and
maintenance. Although previous studies have suggested that host-
type Tregs show a temporary expansion immediately after HSCT
after non-myeloablative conditioning, the kinetics of host-Tregs
after HSCT is left out from this schema to simply discuss the donor-
Treg engrafting processes.
Phase 1: Expansion of Graft-Derived Tregs
During the first month post-HSCT, donor stem-cell graft-derived
mature Tregs promptly expand in response to lymphopenia and
alloantigens. The expansion peaks around the first month after
HSCT and appears to be contracted by activation-induced cellFrontiers in Immunology | www.frontiersin.org 4death (AICD). It remains unclear whether some part of graft-
derived Tregs would survive as functional memory suppressor
cells for a long time after HSCT (38).
Phase 2: Transition of Peripheral
Treg Source
The emergence of HSC-derived Tregs is generally delayed
because of thymic dysfunction after HSCT; therefore, the total
number of Tregs in the periphery decreases after the contraction
of graft-derived Tregs (transitional phase). The decline in the
number of Tregs in this phase may be associated with the late
onset of acute GVHD or overlap syndrome.
Phase 3: Repopulation and Relocation of
Thymus-Generated Tregs
After a dip in the number of Tregs in Phase 2, it takes about a
year for the number of circulating Tregs to increase and
approach the normal range. It is much faster than the
reconstitution of Tcon subsets, which often reach a normal
range within over 2 years (16). Treg repopulation in this phase
is mainly constituted by HSC-derived Tregs. Although thymic
generation of Tregs is markedly impaired after HSCT, newly
generated Tregs maintain higher levels of proliferation during
this phase. Proliferation of Tregs is relatively aggressive as
compared to other Tcons, resulting in high levels of the Treg/
Tcon ratio and the Treg/CD8T ratio in this phase (16, 17). TheFIGURE 3 | Basic framework of Treg reconstitution after HSCT. The basic
framework of Treg recovery after HSCT consists of four phases. In the first
month after HSCT, lymphopenia-driven peripheral proliferation of graft-derived
Tregs (shown in green) induces the initial expansion of this subset, which is
important for preventing acute GVHD (Phase 1). The total number of Tregs
transiently decrease between the contraction of expanded graft-derived Tregs
and the emergence of HSC-derived Tregs (shown in red) (Phase 2).
Prolonged lymphopenia in the first year promotes the continuous aggressive
proliferation of HSC-derived Tregs, which contributes to the recovery of total
Treg cells and provides an essential basis for long-term immune tolerance
(red solid line) (Phase 3). However, highly proliferative Tregs can fail to
maintain homeostasis due to the high susceptibility to apoptosis, and
exhaustion of the Treg population could be a trigger for refractory GVHD
(red dotted line) (Phase 4). GVHD, graft-versus-host disease; Treg, regulatory
T cell; HSC, hematopoietic stem cell.August 2021 | Volume 12 | Article 713358
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related natural thymic involution, thus Treg kinetics in Phase 3
should be carefully evaluated in the pediatric transplant cohorts.
Phase 4: Maintenance of HSC-
Derived Tregs
As only naïve Tregs are capable of aggressive proliferation, the
stable emergence of naïve Tregs from the thymus is thought to be
critical for the maintenance of Treg homeostasis. Tregs can
repopulate by compensatory homeostatic proliferation in Phase
3, even in patients with severe thymic damage; however, high
levels of Treg proliferation in prolonged lymphopenia are
counterbalanced by increased susceptibility to apoptosis, 6–9
months after HSCT. Importantly, peripheral depletion based on
abnormal homeostasis is observed only in Tregs, but not in other
Tcons, resulting in the imbalance of lymphocyte subsets, which
provides a fundamental basis for the development of chronic
GVHD (16, 39, 40).
Treg Migration After HSCT
Appropriate circulation and localization of Treg are crucial
for systemic immune suppression. Luciferase-expressing
Tregs enabled tracking the tissue migration and survival of
Treg longitudinally in mice HSCT model. Transferred Tregs
proliferated in secondary lymphoid organs and sequentially
migrated and localized into peripheral tissue after allogeneic
stimulation in vivo (41). The initial priming of Tregs occurring in
the secondary lymph node required CD62L expression on Tregs
to migrate into lymphoid organs and protect from GVHD
lethality (42). The proinflammatory environment during the
early period after HSCT is essential for early Treg expansion
and migration to GVHD sites. These Tregs exhibited sufficient
suppressive function for alloreactive effector T cell proliferation
in lymphoid organ and peripheral tissue (41).
The above model of Treg reconstitution is based on
the number of Tregs in peripheral blood after clinical
transplantation (16, 17). Most clinical studies test Tregs in
peripheral blood rather than lymph nodes or target peripheral
tissues, while mouse studies often test Tregs in the spleen and
lymph nodes. Therefore, interpretation of the results needs to be
carefully considered. Tregs at each site after HSCT may have
different properties and functions for the overall regulation of
allogeneic immunity.EFFECTS OF LOW-DOSE IL-2 ON
TREG HOMEOSTASIS
IL-2 and Treg
It was initially found that IL-2 stimulates naïve T cell
proliferation and generates effector and memory T cells. Later,
several reports have shown that the germline knockout of IL-2
(43, 44) or blocking of IL-2 (45) or CD25 (46) results in
autoimmune diseases, suggesting that IL-2 plays an essential
role in immune tolerance. After identifying Tregs, IL-2 is now
known as a critical homeostatic cytokine for Treg function (47),Frontiers in Immunology | www.frontiersin.org 5Treg differentiation in the thymus, and Treg expansion in the
periphery (48, 49). The IL-2 receptor (IL-2R) is expressed as an
intermediate-affinity dimer (IL-2Rb and IL-2Rg) or high-affinity
trimers, which include IL-2Ra (CD25). Tregs constitutively
express high-affinity to IL-2 receptors, which enables Tregs to
respond to a small amount of IL-2, which other T cell subsets do
not respond to. Initially, low-dose IL-2 was used to prevent
disease recurrence owing to the GVT effect from natural killer
(NK) cells, which also express CD25 in a steady state (50). In this
pioneering study, low-dose IL-2 (2–6 × 105 IU/kg/day) was
administered for up to 3 months, and only one patient
developed acute GVHD. Although the effect of low-dose IL-2
on lymphocyte subsets could not be fully evaluated because Treg
had not been defined at the time of the study, the follow-up study
revealed that the use of low-dose IL-2 induced the increasing
Tregs in patients (51). The results led to the subsequent project of
low-dose IL-2 therapy which aimed to reconstruct immune
tolerance by increasing Tregs in patients with chronic
GVHD (52).
Low-Dose IL-2 for Chronic
GVHD Treatment
Based on the theory that Tregs preferentially respond to low-
dose IL-2, we conducted a phase 1 trial of administering low-
dose IL-2 therapy daily in patients with steroid-refractory
chronic GVHD (SR-cGVHD). In this trial, a total of 29
patients were enrolled, and the maximum tolerated dose of IL-
2 was 1 × 106 IU/m2; none of the patients experienced
progression of chronic GVHD or relapse of hematologic
cancers. Of the evaluable 23 patients, 12 patients had a
major response, and the number of CD4+Tregs was
preferentially increased in all patients (53). A subsequent phase
2 trial evaluated the efficacy of daily IL-2 (1 × 106 IU/m2)
administration for 12 weeks in 35 adult SR-cGVHD patients.
The treatment was well tolerated, with 20 of 33 evaluable patients
demonstrating clinical response at multiple chronic GVHD sites.
The phase 2 trial also showed a rapid increase in the absolute
number of Tregs and a rapid increase in the Tregs/Tcons
ratio (54).
To elucidate the biological mechanisms of low-dose IL-2, we
examined the effects of daily IL-2 therapy on the homeostasis of
CD4+ T cell subsets after transplantation (55). We first
demonstrated that chronic GVHD is characterized by
constitutive phosphorylation of Stat5 in Tcon, associated with
elevated levels of IL-7 and IL-15 and relative functional
deficiency of IL-2. This was promptly corrected after IL-2
therapy, which resulted in the selective increase of Stat5
phosphorylation in Tregs and a decrease in pStat5 in Tcons.
This was associated with profound changes in Treg homeostasis,
including increased proliferation, increased thymic export, and
enhanced resistance to apoptosis (55). A single cell mass
cytometry analysis confirmed that low-dose IL-2 preferentially
activated p-STAT5 in Helios+ naïve Tregs (56), promoted an
increase in the population, and enhanced the suppressive
function. In addition to increasing the number of Tregs by
low-dose IL-2, it may also be important to increase the T cellAugust 2021 | Volume 12 | Article 713358
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shown that the limited TCR diversity of Tregs may be associated
with autoimmune diseases (57, 58) and GVHD in the
experimental models (59). A recent study using samples from
patients who received low-dose IL-2 demonstrated that the
increased Treg diversity after IL-2 treatment was associated
with the improvement of clinical symptoms of chronic GVHD
(60). Taken together, low-dose IL-2 therapy restores Treg
homeostasis and promotes the reestablishment of immune
tolerance in patients with chronic GVHD.
To reconsider the optimum algorithm of IL-2 intervention for
safe and efficient Treg expansion, we conducted a murine model
study, and found that the daily administration might not be
required and the intermittent administration within threshold
could be sufficient for the maintenance of expanded Tregs after
the initial intensive IL-2 intervention (61). Based on the idea, we
have designed and started a multicenter phase I/IIa clinical trial
of low-dose IL-2 for patients with SR-cGVHD (62). In the
protocol, IL-2 treatment is composed of two sequential phases:
the induction phase and the maintenance phase. In the induction
phase, IL-2 is subcutaneously administrated once per day for 4
weeks. In the subsequent maintenance phase, IL-2 is
subcutaneously administrated three times per week for
following period up to 1 year. The study had been completed
and showed the favorable results with the stable immunological
and clinical effects (63). Data are now being analyzed
for publication.
Further studies are needed to determine the optimal dosage,
timing, duration, and combination of low-dose IL-2 therapy in
patients with chronic GVHD. Recently, engineered Treg-
selective human IL-2 was developed in humanized mice during
xenogeneic GVHD (64), and Efavaleukin Alfa (AMG-592), a
human IL-2 mutant designed to have greater Treg selectivity and
longer half-life compared with recombinant IL-2, is now under a
clinical trial for patients with SR-cGVHD (NCT03422627).
Additionally, a phase 1 clinical trial focusing on the
combination of donor-Treg infusion followed by low-dose IL-2
for SR-cGVHD is also in progress (NCT01937468).EFFECTS OF IMMUNE-CHECKPOINT
INHIBITORS ON TREG HOMEOSTASIS
Immune checkpoints play an important role in the activation of
effector T cells and the regulation of cytotoxic activity. In
addition to this, previous studies have shown that they play a
pivotal role in the homeostasis and function of Tregs, which
originally exhibit an activated phenotype.
PD-1 is an immune checkpoint receptor that attenuates T-cell
activation by interacting with its ligands, PD-L1 and PD-L2 (65).
However, the exact role of PD-1 in the immune suppressive
function of Tregs remains unclear. PD-1-deficient Tregs
improved the symptoms of autoimmune pancreatitis in a
mouse model (66), while in human glioblastoma tissues, Tregs
expressing a high level of PD-1 had an exhausted phenotype and
reduced immunosuppressive function (67). Moreover, inFrontiers in Immunology | www.frontiersin.org 6patients with gastric cancer who developed hyper-progressive
disease after PD-1 blockade, tumors possessed highly
proliferative Tregs after treatment (68). These studies suggest
that PD-1 may regulate the immunosuppressive function of
Tregs. In contrast, in a mouse chronic infection model, PD-1
blockade attenuated immunosuppression by Tregs, mediated by
direct interaction of PD-1 on Tregs with PD-L1 on CD8+ T cells
(69). These discrepant results regarding the role of PD-1 on the
suppressive function of Tregs might be explained by the
differences in the class of Tregs (70).
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an
inhibitory checkpoint molecule. Tregs constitutively express a
high level of CTLA-4, whereas Tcons express CTLA-4 only after
activation (71). CTLA-4 competes with CD28 for CD80/CD86
ligands, resulting in the inhibition of co-stimulatory signals (72).
CTLA-4 blockade was the first immune checkpoint inhibitor
(ICI) approved for clinical use, and the mechanisms of the anti-
CTLA-4 blockade were distinct from those of PD-1 blockade (73,
74). Regarding the effect of Tregs, several preclinical studies
indicated that the anti-tumor effects of CTLA-4 blockade were
dependent on the depletion of CTLA-4-expressing Tregs in the
tumor microenvironment via antibody-dependent T cellular
cytotoxicity, leading to an increase in the CD8+/Treg ratio
(70). However, anti-CTLA-4 immunotherapy for patients with
solid cancers did not deplete Tregs (75); therefore, further
analyses to address the role of CTLA-4 in Tregs in various
settings are warranted.
The Effect of PD-1 on Treg Homeostasis
During Low-Dose IL-2 Therapy
Low-dose IL-2 therapy increased circulating Tregs and improved
clinical symptoms of chronic GVHD; however, the mechanisms
that regulate Treg homeostasis during IL-2 therapy have not
been well studied. To elucidate these regulatory mechanisms, we
examined the role of inhibitory coreceptors on Tregs during IL-2
therapy in a murine model and in patients with chronic GVHD
(76). Murine studies demonstrated that low-dose IL-2 selectively
increased Tregs and simultaneously enhanced the expression of
PD-1, especially on CD44+CD62L+ central-memory Tregs,
whereas the expression of other inhibitory molecules, including
CTLA-4, LAG-3, and TIM-3 remained stable. PD-1-deficient
Tregs showed rapid Stat5 phosphorylation and proliferation
soon after IL-2 initiation; however, Tregs became proapoptotic
with higher Fas and lower Bcl-2 expression. As a result, the
positive impact of IL-2 on Tregs was completely abolished, and
Treg levels returned to baseline despite continued IL-2
administration (Figure 4). We also examined circulating Tregs
from patients with chronic GVHD who were receiving low-dose
IL-2 and found that IL-2-induced Treg proliferation was
promptly followed by increased PD-1 expression on central-
memory Tregs. Notably, clinical improvement of GVHD was
associated with increased levels of PD-1 on Tregs, suggesting that
the PD-1 pathway supports Treg-mediated tolerance. These
studies indicate that PD-1 is a critical homeostatic regulator of
Tregs by modulating proliferation and apoptosis during IL-
2 therapy.August 2021 | Volume 12 | Article 713358
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After HSCT
It has been observed that PD-1 blockade therapy is an effective
strategy for hematological malignancies such as classical
Hodgkin lymphoma (cHL) and it has made it possible to
bridge chemotherapy-refractory patients to allogeneic HSCT
(77–79). However, PD-1 blockade during the peri-transplant
period theoretically enhances the donor effector T cell response,
leading to an increased risk of severe GVHD. A pioneering
murine model study demonstrated that PD-1 blockade potently
enhanced T cell alloresponses both in vitro and in vivo, and the
effect of PD-1/PD-L1 blockade was largely dependent on interferon
(IFN) production (80). A subsequent study evaluating the role of
PD-1 ligand for GVHD demonstrated that PD-1/PD-L1 blockade,
but not PD-1/PD-L2 blockade, markedly accelerated GVHD
lethality; suggesting an important differential role of host PD-L1
and PD-L2 in controlling GVHD (81). In the clinical setting,
retrospective studies reported that pretransplant PD-1 blockade
increased the risk of severe acute GVHD (82–84). Nieto et al.
investigated clinical samples of patients treated with nivolumab
before HSCT and demonstrated that nivolumab was detectable in
the plasma for up to 56 days after HSCT was performed, and this
residual nivolumab could bind to and block PD-1 expressed on
donor effector T cells during this period. They also showed that
pretransplant nivolumab resulted in a high frequency of IFN-g-
producing effector T cells, which might contribute to severe GVHD
after transplantation (85).
Our group examined the effect of PD-1 blockade on Treg
homeostasis after allogeneic HSCT in murine models and human
clinical samples. First, we demonstrated that pre- and peri-
transplant PD-1 blockade increased the severity of GVHD due
to the unbalanced reconstitution of T cell subsets in recipient
mice with PD-1 inhibition (86). PD-1-/- effector T cells
aggressively increased after HSCT, whereas PD-1-/- Tregs couldFrontiers in Immunology | www.frontiersin.org 7not maintain the expansion due to high susceptibility to apoptosis,
leading to an unbalanced reconstitution of T cells, resulting in lethal
GVHD. Interestingly, post-transplant cyclophosphamide (PTCy)
restored the well-balanced reconstitution of T cell subsets and
prevented tissue damage after HSCT from donor PD-1-/- effector
T cells. Based on fundamental data from a murine study, we
examined clinical samples from patients who underwent HSCT.
The clinical sample analyses revealed that PTCy promoted vigorous
recovery of Tregs in recipients who underwent HLA-haploidentical
transplantation following nivolumab therapy (87). These results
suggest that PD-1 plays a crucial role in Treg homeostasis, especially
in the early phase after HSCT.Moreover, PTCymight be an optimal
GVHD prophylaxis when regulatory PD-1 signaling is functionally
abolished by therapeutic intervention before HSCT (Figure 5).
In fact, recent clinical data have clearly indicated that PTCy was
associated with a low incidence of severe GVHD in recipients with
pre-transplant ICIs (88–91). Furthermore, Merryman et al. recently
reported the results of an international retrospective study that
included 209 relapsed or refractory cHL patients who underwent
HSCT after PD-1 blockade (91). They demonstrated that PTCy-
based haploidentical HSCT was associated with significant
improvements in the progression-free and relapse-free survival of
GVHD as compared with HLA-matched HSCT without PTCy.
This suggests that pretransplant ICI and subsequent PTCy-based
HSCT may provide better GVHD control along with better disease
control (88–91). Further investigations on the impact of peri-
transplant ICIs and PTCy on GVT activity are warranted.
The Effect of PTCy on Treg Homeostasis
After HSCT
PTCy is a novel GVHD prophylactic strategy for acute GVHD
after HSCT from an HLA-haploidentical donor (92), and has
been extended to an HLA-identical donor as a single agent
GVHD prophylaxis (93–95). The mechanisms underlying theFIGURE 4 | The role of PD-1 in Treg homeostasis during low-dose IL-2 therapy. Low-dose IL-2 therapy increases PD-1 expression on Tregs, and PD-1 preserves
sustainable Treg homeostasis during low-dose IL-2 therapy, resulting in the preferential expansion of Tregs and the clinical improvement of chronic GVHD symptoms
(A). In contrast, without sufficient PD-1 signaling, low-dose IL-2 therapy accelerates Treg expansion soon after initiation, but Tregs are predisposed to the
proapoptotic status and cannot maintain the expansion (B). IL-2, interleukin 2; PD-1, programmed cell death 1; Treg, regulatory T cells.August 2021 | Volume 12 | Article 713358
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(96), preserving hematopoietic stem cells and Tregs by their high
expression of aldehyde dehydrogenase (97). The indispensable
role of donor-derived Tregs in preventing GVHD in PTCy was
shown in a mouse model (98), which suggests that PTCy-based
GVHD prophylaxis may preferential ly promote the
reconstitution of Tregs in a clinical setting. However, there are
limited data on Treg reconstitution after HSCT with PTCy-based
GVHD prophylaxis using human clinical samples (99–102). Our
and other groups recently reported the reconstitution of
lymphocyte subsets between HLA-haploidentical PTCy-based
HSCT (PTCy-haplo) as compared to HLA-identical donor
HSCT using conventional GVHD prophylaxis (101, 102).
These studies demonstrated that the number of T cells was
significantly lower in PTCy-haplo than that in HLA-identical
HSCT in the early phase, which was due to slower CD4+Tcons
reconstitution. On the other hand, the recovery of Tregs after
PTCy-haplo was earlier than that after HLA-identical HSCT,
resulting in a significantly higher Tregs/Tcons ratio during the
first 3 months after HSCT (101, 102). Although PTCy is a
promising approach in terms of Treg reconstruction, further
optimization of prophylaxis is required, including the optimal
dose and duration of cyclophosphamide administration, the
timing of calcineurin inhibitor initiation, and combining it
with other immunosuppressant drugs.EFFECTS OF OTHER IMMUNE
MODULATORS ON TREG HOMEOSTASIS
Anti C-C Chemokine Receptor 4 Blockade
C-C chemokine receptor 4 (CCR4) is a chemokine receptor
expressed in most patients with adult T-cell leukemia lymphomaFrontiers in Immunology | www.frontiersin.org 8(ATLL). Mogamulizumab (Mog) is a humanized anti-CCR4
immunoglobulin G1 monoclonal antibody that has an almost
50% efficacy in patients with relapsed or refractory ATLL (103,
104). CCR4 is also highly expressed on Tregs; therefore,
pretransplant Mog may affect post-transplant Treg homeostasis
and the incidence of GVHD. A multicenter, retrospective study
demonstrated that pretransplant Mog was significantly associated
with an increased risk of severe acute GVHD (105). Although a
phase 1 study reported the half-life of Mog to be 15 to 18 days,
retrospective data showed that the interval between the last
administration of Mog to HSCT within 50 days was an
independent prognostic factor for non-relapse mortality (105);
therefore, the last treatment schedule of Mog is recommended to
be ≥ 50 days prior to HSCT (106). In addition, the effect of Mog
on Treg recovery after HSCT might be more profound than
expected. We report a case of ATLL in which plasma exchange
(PE) was conducted to eliminate residual Mog to treat severe
GVHD (107). Although plasma Mog concentration was
eliminated, it did not lead to the prompt elevation of Treg levels
in peripheral blood, and the clinical responses of GVHD were
limited to partial remission, suggesting that recovery of donor-
derived Tregs in the acute phase after HSCT is multifactorial, and
the single procedure of PE-based Mog depletion does not
necessarily warrant the quick restoration of Treg homeostasis. As
mentioned above, although Mog is a highly effective treatment for
relapse and refractory ATLL, the increased risk of severe GVHD
cannot be ignored. Avoiding the short interval between the last
administrationofMogandHSCTanddonors at high risk ofGVHD
should be considered to reduce the negative impact ofMog. Having
said that, further clinical and basic research in this field is needed.
a-Galactosylceramide
Although low-dose IL-2 therapy induced the selective expansion
of Tregs in the chronic phase after HSCT, the specificity of theFIGURE 5 | The role of PD-1 in Treg homeostasis after allogeneic HSCT. PD-1 deficient effector T cells aggressively proliferate after HSCT and produce large
amounts of inflammatory cytokines. The highly inflammatory cytokine milieu accelerates the proliferation of PD-1 deficient Tregs, but they cannot maintain proliferation
due to their high susceptibility to apoptosis. Unbalanced reconstitution of T-cell subsets results in severe GVHD (A). In contrast, with PTCy intervention, alloreactive
proliferative effector T cells are efficiently eliminated, contributing to reduced inflammatory cytokine production. It enables Tregs to restore the appropriate levels of
proliferation and maintain homeostasis, which contributes to the prevention of severe GVHD (B). PD-1, programmed cell death 1; Treg, regulatory T cell; Teff, effector
T cell; PTCy, post-transplant cyclophosphamide.August 2021 | Volume 12 | Article 713358
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activated effector T cells also express CD25 and may respond to
the administered IL-2. In contrast, previous murine studies have
demonstrated that invariant natural killer T (iNKT) stimulation
mediated by a-galactosylceramide (a-GC) enables selective Treg
expansion even in the very early phase following HSCT. iNKT
cells are unique immunoregulatory T cell subsets that have
limited TCR repertoires and recognize lipid antigens presented
by CD1d on antigen-presenting cells (108). a-GC is a glycolipid
originally purified from a marine sponge (109) and is also a
ligand for iNKT cells in a CD1d-restricted manner. Previous
studies have shown that a-GC stimulates different iNKT cell
subsets depending on the method of injection (110). In the
murine HSCT model, a single injection of aGC on day 0 after
HSCT promoted Th2 polarization of donor T cells and the
expansion of Tregs in a STAT6-dependent manner, which
resulted in the reduced GVHD mortality (111, 112).
Thereafter, a liposomal a-GC (lipo a-GC) was developed
(113), and lipo a-GC was found to be safe and effective for
acute GVHD prophylaxis in a murine model (114). Regarding
the homeostasis of Tregs, a subsequent study revealed that host
NKT cells induced an IL-4-dependent expansion of donor Tregs
after HSCT (112). In addition, the adoptive transfer of donor
iNKT cells ameliorated GVHD by expanding donor Tregs, in
turn preserving the GVT effect (115). In addition to the acute
GVHD model, our murine study using chronic GVHD models
showed that a-GC treatment could ameliorate chronic GVHD
symptoms through the early expansion of donor-derived Tregs
followed by the suppression of follicular helper T cells and
germinal center B cells (116). Based on the data of preclinical
models, a phase 2 clinical study evaluated the efficacy of RGI-
2001, a novel liposomal formulation of a synthetic derivative of
a-GC in patients who underwent HSCT. A total of 29 patients
received RGI-2001 on day 0 after HSCT, and 28% of recipients
responded to RGI-2001 and increased the frequency and number
of Tregs. These responders developed grade II to IV acute GVHD
significantly less frequently than non-responders (117),
suggesting that a-GC may prevent acute GVHD via Treg
expansion in a clinical HSCT setting.
The combination of a-GC with other therapeutic modalities
may be promising for further effective Treg modulation since the
working mechanism of a-GC is unique and does not overlap
with those of other therapies. Recently, we evaluated the effect of
adding lipo a-GC after PTCy on GVHD and the GVT effect
using the murine GVHD model (118). We demonstrated that a
reduced dose of PTCy followed by adjuvant a-GC enhances the
GVT effect without sacrificing GVHD suppression. Phenotypic
analyses revealed that donor-derived B cells presented the ligand
and induced preferential skewing to the NKT2 phenotype rather
than the NKT1 phenotype, which was followed by the early
recovery of all T cell subsets, especially Tregs. Our results
propose the possibility of a novel strategy for optimizing
PTCy-based transplantation.
Anti-IL-2 Antibody
As the IL-2 receptors express on the activated effector T cells, the
antibody for the IL-2 receptor has been investigated for GVHDFrontiers in Immunology | www.frontiersin.org 9prophylaxis and treatment. However, as IL-2 is an essential
cytokine for Treg survival (45), the clinical effects of IL-2
receptor blockade appear not to be straightforward in patients
after HSCT. Two IL-2 receptor antagonists, basiliximab and
daclizumab, were added on the standard GVHD prophylaxis
and explored the prophylactic effects against GVHD. These
agents showed the preventive effect against acute GVHD, and
basiliximab showed a superior prophylactic effect against chronic
GVHD (119). However, the subsequent prospective randomized
control study showed no additional prophylactic effect of
daclizumab for acute GVHD, and rather it increased the risk
of chronic GVHD and decreased the risk of disease recurrence
(120). In the treatment setting, daclizumab has shown efficacy for
a part of patients with steroid-refractory acute GVHD in the
initial phase 2 trial (121), but the subsequent randomized control
study showed a significantly worse survival rate in patients
receiving corticosteroid with daclizumab than corticosteroid
with placebo (122).
Denileukin diftitox is a genetically engineered protein
composed of human IL-2 fused to diphtheria toxin and has
cytotoxicity against activated T cells based on preferential
binding to the high-affinity IL-2 receptor. A phase 1 study was
conducted to evaluate the safety and efficacy of denileukin
diftitox for 32 patients with SR-acute GVHD. Overall, 71% of
evaluable patients achieved an overall response, including 33% of
complete remission and 38% partial response (123). However,
animal studies suggested that it could affect Treg homeostasis,
and a case study reported that fatal hyperacute GVHD following
denileukin diftitox treatment (124–126)
These inconsistent results may be attributed that anti-IL-2
antibody could affect the homeostasis of both Tregs and activated
Tcons those expressing the IL-2 receptor. It suggests that anti-IL-
2 antibody influence the patient’s immunity differently based on
the balance between Tregs and activated Tcons in each patient
basis, and the possible duality of the effect should be taken into
account when these agents are used for patients after HSCT.
Tyrosine Kinase Inhibitors
Standard GVHD prophylaxis in recipients with HLA-matched
identical donor consists of the combination of calcineurin
inhibitor (CNI) and short-term methotrexate. CNI reduced IL-2
transcription and activation of effector T cells and is a critical agent
to regulate post-transplant immune reaction but have been shown
to be disadvantageous in maintaining Tregs reconstitution because
CNI inhibits the production of IL-2 from activated Tcons (127).
Recently, novel immune modulating agents targeting Janus kinase
(JAK), Bruton’s tyrosine kinase (BTK), or Interleukin-2 inducible
tyrosine kinase (ITK) have been emerged.
Ruxolitinib (RUX) is a selective JAK1/2 inhibitor, and RUX
reduced the GVHD histology score and prolonged survival in a
murine GVHD model. RUX treatment suppressed the signals of
inflammatory cytokines while sparing the IL-2–JAK3–STAT5
signal, which could lead to reduced CD4+IFN-g+ cells and an
increase of Tregs (128). In the human clinical setting, a phase 3
randomized trial compared the efficacy and safety of RUX with
the investigator’s choice. The overall response was significantly
higher in the RUX group, and RUX treatment significantlyAugust 2021 | Volume 12 | Article 713358
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treatment (129).
Regarding BTK and ITK pathways, Ibrutinib, a BTK/ITK
inhibitor, reduced the severity of chronic GVHD using two
established chronic GVHD mice models (130). A phase 1b/2
study showed the safety and efficacy of ibrutinib treatment for
patients with SR-cGVHD (131). While the significance of BTK
inhibition on Treg homeostasis remains unknown, some studies
showed that ITK inhibition might increase Tregs in murine
models (132). Mammadli et al. reported that ITK-deficient donor
T cells significantly reduced inflammatory cytokines leading to
less GVHD intensity in the mice model (133). We recently
demonstrated that pharmacological inhibition of ITK on donor
T cells could ameliorate acute GVHD without sacrificing the
GVT effect (134). In the study, we showed that ex-vivo graft
manipulation with ITK inhibitor modulated donor CD4+ T cell
differentiation towards Th1, Th2, and Th17 with sparing Tregs,
resulting in the prolonged overall survival after HSCT.
Adoptive Transfer of Tregs
In addition to the pharmacological in vivo modulation of Treg
homeostasis described above, the GVHD-preventive effect of
adoptive transferred donor-type Tregs has been evaluated in
murine models and clinical studies. The adoptive transfer of
Tregs enables to increase in the Treg pool at least transiently, and
it may provide merit especially in patients having insufficient
thymic recovery. The initial experimental study demonstrated
that the adoptive transfer of Tregs to the graft suppressed the
expansion of alloreactive donor T cells without impairing the
GVT effect (18). In a human acute GVHD prophylaxis setting, a
first in human clinical trial evaluated ex-vivo expanded umbilical
cord blood (UCB)-derived Tregs for patients receiving
nonmyeloablative double UCB transplantation (135). Tregs
were isolated and cultured with anti-CD3/anti-CD28
monoclonal antibody-coated beads supported by IL-2. A total
of 1-30 x 105/kg UCB-derived Tregs infused on day+1 for all
participants and day+15 for an additional cohort. GVHD
prophylaxis consisted of cyclosporine and mycophenolate
mofetil (MMF), but later changed to sirolimus and MMF due
to potential interference with Treg function and survival by
cyclosporine. Grade II to IV acute GVHD and the incidence of
chronic GVHD were lower than the historical control. The
subsequent study from the same group demonstrated the safety
and efficacy of UCB-derived Treg expanded with K562 cells. This
novel approach enabled the expansion of Tregs to up to 30 times
higher than the previous method. In this study, the rate of grade
II to IV acute GVHD was lower than the control without
increasing the infection and relapse rates (136). The Perugia
group infused Tregs followed by stem cell and Tcons infusion
without immunosuppression therapy after transplantation. They
conducted a phase 2 study evaluating the effect of isolated
donor Tregs (1 x 106/kg) on day-4, followed by a purified
CD34+ and Tcons (1 x 106/kg) on day0 without posttransplant
immunosuppression for patients receiving HLA-haploidentical
transplantation (137). In this setting, purified Tregs and Tcons
were harvested from the same donor as the stem cell harvest and
not cultured ex-vivo. The incidence of grade II to IV acuteFrontiers in Immunology | www.frontiersin.org 10GVHD was 15%, and this rate of acute GVHD was similar to
the historical controls. Surprisingly, although the high-risk
patients’ background, the relapse rate was significantly lower
than the historical control group, suggesting that adoptive
transfer of Tregs followed by Tcons and CD34+ stem cells as
acute GVHD prophylaxis strategy suppress GVHD without
abrogating the GVT effect in a human setting. Recently, a
subsequent study involving fifty HLA-haploidentical transplant
recipients with Treg adoptive transfer showed excellent results
(138). Fifteen patients developed grade II to IV acute GVHD,
including 12 grade III to IV, and all recipients were treated with
corticosteroids. Only 5 patients were refractory to first-line
steroid therapy, and 3 of them recovered after the second-line
treatment. Of note, only 2 patients relapsed, and the moderate/
severe chronic GVHD/relapse-free survival was 75%.
On the contrary, the data of adoptive transfer of Tregs in the
treatment setting of active ongoing acute GVHD treatment was
limited. Two case series described the use of ex-vivo expanded
Treg infusion for the treatment of acute GVHD and chronic
GVHD (139, 140). These studies demonstrated the feasibility of
the ex-vivo Treg expansion and infusion, but the effect of this
approach should be evaluated by larger clinical trials.
To maintain transferred Tregs in vivo, low-dose IL-2
administration after adoptive transfer of Tregs is theoretically
attractive. In a phase 1 study, 24 SR-cGVHD patients received
freshly isolated Tregs from the original stem cell donor followed
by IL-2 (1 x 106 U/m2/day) treatment for 8 weeks. The response
rate was 33%, and TCRb diversity in Tregs is normalized with
therapy (141). Larger clinical trials are warranted to confirm the
efficacy of this combination therapy in patients with SR-cGVHD.EMERGING PROBLEMS AND
FUTURE PERSPECTIVES
Ever since the discovery, Tregs have been the focus of many
studies owing to the efficient immunosuppressive function. In
the allogeneic HSCT, as Tregs have a central role in the
regulation of post-transplant immunity, the dynamics of Tregs
have been extensively studied in murine models and clinical
samples. As described in this review, Tregs originally have
different characteristics in homeostasis from conventional T
cell subsets, and understanding the unique homeostasis makes
it possible to give Tregs selective effects in vivo. However, there
remain many unresolved questions about Treg homeostasis
in patients.
First, one of the critical problems is the localization of Tregs
in a human clinical setting. Previous studies suggest that the
phenotype and function of Tregs are different depending on the
localization, such as lymph nodes, target tissues, and tumor
micro-environments. For example, in patients with gastric
cancer, Treg phenotype is different between tumor infiltrating
Tregs and peripheral circulating Tregs (68). Most of human
GVHD clinical studies depended on the circulating Tregs, hence,
an evaluation of Treg localization and the function in each
specific site would be helpful for our further understanding of
Treg homeostasis in the context of GVHD.August 2021 | Volume 12 | Article 713358
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well characterized in human clinical transplant (142). To further
elucidate the Treg effect on the GVT, further research is needed
to develop clinically-relevant murine models to study anti-tumor
immunity after allogeneic HSCT.
Third, the effect of novel immunotherapies on the Tregs has
not been well studied. Recent developments of immunotherapies
such as chimeric antigen receptor T cell (CAR-T), bispecific T-
cell engagers (BiTE), and ICIs have provided significant progress
for treatment. Despite improvement in the response rate,
patients with refractory diseases still often require post-
remission therapy with HSCT. The effects of a previous history
of CAR-T or BiTE on subsequent allogeneic HSCT are largely
unknown. In particular, it is important to study the effect of
pretransplant novel immunotherapies on donor-derived
immune cell recovery, including Tregs, after allogeneic HSCT.
Advances in the understanding of Treg homeostasis in patients
after HSCT may contribute to the treatment for autoimmune
diseases and solid cancers. In solid cancers, Tregs negatively
influence tumor control; therefore, contrary to GVHD, reducing
Tregs and activating effector T cells may promote the anti-tumor
effect. Based on our previous reports regarding the role of PD-1 on
Tregs after low-dose IL-2 and HSCT (76, 86), the combination
treatment IL-2 and PD-1 blockade may activate effector T cell and
promote Treg apoptosis in the inflammatory environment, like a
tumor microenvironment.
Novel experimental methodologies may enable us to
overcome the remaining issues shown here. In fact, the single-
cell technique made detailed characterization of cells and their
microenvironment, and to answer questions that could not beFrontiers in Immunology | www.frontiersin.org 11addressed by the conventional technique (143). In the context of
acute GVHD, scRNA-seq has identified a novel regulator of T
cell alloimmunity (144). Previous research has investigated the
role of long noncoding RNA after HSCT using scRNA-seq and
identified Linc00402 as a regulator of allogeneic T cell function.
In addition, the TCR sequence method provides information on
the TCR diversity and clonality of these populations. Since each
T cell possesses its own unique TCR, TCR-seq allows for
sensitive tracking of T cells at the clonal level (145). These
novel approaches may solve the limitations of previous studies
by conventional approach and provide a bridge to new findings
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